Exploring data for clinical trials by therapeutic focus, we can see areas where specific countries may have competitive advantage based on scientific excellence and clinical opportunity. For cardiovascular and metabolic treatments, the UK follows closely behind Germany and Japan as significant sites for clinical research. The US retains the majority of trials, however the notable trend appears to be a decline in the number of trials since 2013. This is most marked in the US, but all countries have seen a decline in clinical trials in this area; this is a likely reflection of product pipeline rather than as a result of global competition for trials in cardio-metabolic disease.
Only commercial trials related to pharmaceutical drug development and molecular/biological entities were included. Collaborative trials were only included if one or more partners were a commercial organisation and all therapeutic areas were included in this analysis. Trials across multiple therapy areas were only included once and the therapy area in which they were included was determined by the trial’s main purpose for study.